Table 3.
Univariate and multivariate1 analysis for cancer-specific survival and overall survival in the patients with EGJ adenocarcinoma (n = 188)
| No. patients (%)Positive/negative | No. events (%)Events/n | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P-value | HR | 95% CI | P-value | |||
| Cancer-specific survival | ||||||||
| CEA | 39 (21)/149 (79) | 23 (12)/188 | 2.70 | 1.12–6.16 | 0.028 | 1.33 | 0.53–3.15 | 0.533 |
| CA19-9 | 24 (13)/164 (87) | 23 (12)/188 | 4.30 | 1.73–9.93 | 0.003 | 3.89 | 1.41–10.33 | 0.010 |
| Overall survival | ||||||||
| CEA | 39 (21)/149 (79) | 34 (18)/188 | 2.07 | 0.97–4.17 | 0.060 | —2 | —2 | 2 |
| CA19-9 | 24 (13)/164 (87) | 34 (18)/188 | 2.90 | 1.28–6.01 | 0.013 | 2.43 | 1.03–5.35 | 0.043 |
The P-value for significance was adjusted to P = 0.05/4 = 0.0125. Thus, a P-value between 0.05 and 0.0125 should be regarded as of borderline significance. EGJ esophagogastric junction; HR, hazard ratio; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9.
1
Adjusted for age, sex, tumor location by Siewert classification, depth of tumor invasion, lymph node metastasis, distant metastasis, histopathological types, and treatment method.
2
CEA variable was not included in the final model of multivariate analysis because of backward elimination (P > 0.05).